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Bypass grafting remains a common and effective
treatment for end-stage coronary, peripheral, renal,
and visceral atherosclerosis. At the present time, over
1,000,000 vein grafts are implanted annually in the
United States. Despite initial technical success, the
development of vein graft stenosis within 2 years
after implantation occurs in up to 50% of the grafts
and frequently leads to graft thrombosis and end-
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were excised and assayed for genomic D Rb DNA with the polymerase chain reaction or
for hemagglutinin molecule expression and localization with immunohistochemistry.
The remainder of the grafts (n = 36) were perfusion-fixed after 4 weeks, and 5 m m sec-
tions prepared for digital planimetric analysis.
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organ failure, including myocardial infarction and
extremity amputation.
Although all veins thicken when subjected to
the increased wall tension from arterialization, some
grafts respond inappropriately with excessive vascu-
lar smooth muscle cell (VSMC) proliferation and
the development of occlusive lesions.1-4 Recent
advances in vector design and gene transfer tech-
nology now make it feasible to genetically modify
vein grafts at the time of implantation, which possi-
bly renders them less susceptible to VSMC over-
growth and stenosis. The intraoperative modifica-
tion of vein grafts through gene transfer is an attrac-
tive approach, given the natural access to target
tissue at the time of operation and the avoidance of
systemic vector exposure. The purpose of this
experiment was to test the hypothesis that induced
overexpression of a cytostatic nonphosphorylatable
form of the retinoblastoma protein ( D Rb) would
attenuate vein graft neointimal thickening in an
experimental model.
METHODS
Vector preparation. An adenoviral vector
(AdD Rb) was constructed that encoded a nonphos-
phorylatable, constitutively active form of D Rb that
contained a 10–amino acid, NH2-terminal epitope
tag from the influenza hemagglutinin molecule
(HA; Fig 1). In this vector, transcription of the D Rb
gene was controlled by the cellular elongation fac-
tor–1 a promotor5 and the 4F2 heavy chain
enhancer.6,7 The control virus, AdBglII, was identi-
cal to Ad D Rb except for the absence of the D Rb
sequence and the HA tag.
The vectors were constructed with recombina-
tion in 293 cells between plasmid DNA and E1-
deleted and E3-deleted Ad5Sub360 adenovirus
DNA digested with Xba and Cla I. High titer stocks
were prepared by infecting 293 cells with 2 to 5
plaque-forming units (PFU) of virus per cell. Viral
lysates were purified with centrifugation in discon-
tinuous CsCl gradients, and titers were determined
from the absorbance at 260 nm of the purified virus
preparation (1 absorbance unit = 1010 PFU/mL).
Aliquots (200 to 400 m l) were stored at –70°C in
Dulbecco’s phosphate-buffered saline solution
(PBSS) in the absence of CaCl2 and MgCl2, and
were thawed on the day of transfer.
Animal experiments. Male New Zealand white
rabbits (3.5 to 4 kg) that had been fed normal rabbit
chow underwent anesthesia with intramuscular injec-
tions of ketamine hydrochloride (40 mg/kg) and
xylazine hydrochloride (5 mg/kg) augmented with
halothane via endotracheal intubation. Antibiotic
prophylaxis was provided with enrofloxacin 10
mg/kg intramuscularly daily. Using sterile technique,
the external jugular vein was exposed with 4.5 ·
loupe magnification and the two branches were can-
nulated with 24-gauge catheters. One cannula was
used for irrigation and transfection, and the other
was used for intraluminal pressure monitoring
(Hewlett-Packard 78534B, Palo Alto, Calif). The
proximal vein was ligated, and the main channel was
gently irrigated with saline solution and emptied.
Then, 0.5 mL of 3 · 1010 PFU/mL AdD Rb (n =
16), 3 · 1010 PFU/mL control adenovirus (AdBglII;
n = 15), or vehicle (PBSS; n = 17) was statically
instilled into the vein for 10 minutes at 120 mm Hg.
After vector exposure, the vein was emptied,
excised, and placed in PBSS at room temperature.
Heparin (200 U/kg) was administered intravenous-
ly. The ipsilateral common carotid artery was isolat-
ed and bathed with papaverine hydrochloride to pre-
vent spasm. The vein was fashioned as an end-to-side
common carotid interposition graft, and the inter-
vening common carotid artery segment was ligated
and divided (functional end-to-end bypass graft).
After unclamping, graft length and external diame-
ter were measured with digital calipers (Ultra-Cal II,
Fred V. Fowler Co, Newton, Mass). Mean blood
flow was measured with an ultrasonic transit-time
flowmeter (Transonics Systems Inc, Ithaca, NY),
and flow waveforms were recorded at 200 Hz for 10
seconds with a digital acquisition system (Lab
Master D.M.A., Scientific Solutions, Inc, Solon,
Ohio). The incision was closed in two layers, and the
animal was allowed to recover.
Identification of genomic DNA. After 5 days,
six grafts (two from each group) and contralateral
jugular veins were excised for identification of
transgenomic DNA. Genomic DNA was isolated
with a previously described protocol.8 Briefly, vein
graft tissue samples (~200 m g) were digested over-
night at 55°C in tissue lysis buffer (50 mmol/L Tris-
HCl, 100 mmol/L ethylenediamine tetra-acetic
acid, 0.5% sodium dodecylsulfate, 500 m g/mL pro-
teinase K, pH 8.0). Subsequently, samples were
Fig 1. AdD Rb vector.
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extracted with phenol, phenol/CHCl3, and CHCl3
followed by EtOH precipitation. DNA was resus-
pended in 300 m L TE (10 mmol/L Tris, 1 mmol/L
ethylenediamine tetraacetic acid, pH 8.0). The
quality of DNA was checked with primers specific 
to the rabbit b -globin gene 5’-GAATGGTGC-
ATCTGTCCAGTGAG (sense) and 5’-GAGAAAG-
GCAGGATGATGACCAGG (antisense). The pres-
ence of the Ad D Rb adenoviral genome was deter-
mined with the polymerase chain reaction using
primers specific for HA D Rb complementary DNA
5 ’ - A A G C T T C C C G G G G A A T T C A C -
CATGGGGTACCCATACGATGTTCCAGAT-
TACG (sense) and 5’-ATAGCATTATCAACCTTG-
GTACTGG (antisense). Amplification products
were detected after electrophoresis on 2% agarose
gels stained with ethidium bromide.
HAD Rb gene expression. After 5 days, six grafts
(two from each group) were excised and imbedded in
paraffin for immunohistochemistry with a monoclon-
al antibody specific for HA. Paraffin was removed,
and the 5 m m sections were hydrated and treated with
H2O2 for 4 minutes at 42°C to inactivate endogenous
peroxidases. The slides were stained with an mAb to
HA (Boehringer-Mannheim, Indianapolis, Ind) for
32 minutes at 42°C. The mAb distinguishes the
recombinant HA D Rb from the wild-type Rb. The
slides then were exposed to biotinylated antibodies to
mouse immunoglobulin G (Ventana Medical Systems,
Tucson, Ariz), avidin-conjugated horseradish peroxi-
dase, and diaminobenzidine plus copper (Ventana)
and lightly counterstained with hematoxylin.
Graft morphometry. The remainder of the
grafts (n = 36) were harvested after 4 weeks for analy-
sis of neointimal thickening. The animals were reanes-
thetized, and the grafts were reexposed. Repeat geo-
metric and flow measurements were obtained. From
cannulation of the proximal common carotid artery,
the grafts were perfused with 3.7% buffered formalde-
hyde at the last recorded systemic blood pressure.
Sections from the proximal, middle, and distal graft
were excised and preserved at 4°C. Five m m sections
were cut and stained with hematoxylin and eosin, and
the intimal and medial areas were measured by means
of digital planimetry with a personal computer–based
workstation as previously described.1 Measured end-
points included luminal circumference (Cl), neointi-
mal/medial border circumference (Cni), and medi-
al/adventitial border circumference (Cm). Calculated
endpoints included luminal diameter (Cl/p ), neointi-
mal thickness ([Cni-Cl]/2 p ), and medial thickness
([Cm-Cni]/2p ).
Vector toxicity. At the time of death, blood was
drawn from nine animals (three in each group) for
determination of serum chemistries (Na, K, Cl,
CO2, glucose, blood urea nitrogen, creatinine), liver
enzymes (bilirubin, alkaline phosphatase, serum glu-
tamate oxaloacetate transaminase, serum glutamate
pyruvate transaminase), coagulation profile (pro-
thrombin time, partial thromboplastin time), and
hematologic parameters (hemoglobin, hematocrit,
leukocyte count, platelet count).
Statistical analysis. All data are reported as the
mean ± the standard error of the mean. Comparison
between groups was performed with the Kruskal-
Wallis one-way analysis of variance (nonparametric
data), with a P of .05 considered significant.
RESULTS
The three groups had similar results with respect
to graft length, external diameter, and mean blood
flow at the time of implantation (Table I). There
were no wound infections, and all the animals sur-
vived to sacrifice. All the grafts that were harvested
at 5 days were patent (n = 6), and 30 of 36 grafts
that were harvested at 4 weeks were patent (occlu-
sions: 3 vehicle, 1 AdBglII, and 2 Ad D Rb). The
occluded grafts were excluded from further analysis.
To confirm DNA quality, b -globin DNA was
identified in grafts and contralateral jugular veins in all
the groups (Fig 2). HAD Rb was identified only in vein
grafts exposed to Ad D Rb. Immunohistochemical
analysis results revealed transgene expression in most
endothelial cells and in many VSMCs in grafts that
were exposed to AdD Rb (Fig 3). There was no evi-
dence for inflammatory cell infiltration using light
microscopy.
After 4 weeks, vein grafts had lengthened approx-
Table I. Graft characteristics at the time of implantation
Vehicle (n = 13) AdBglII (n = 11) AdD Rb (n = 12) P value
Graft length (mm) 25 ± 1 24 ± 1 23 ± 1 NS
External diameter (mm) 4.0 ± 0.2 4.0 ± 0.3 4.1 ± 0.2 NS
Mean blood flow (mL/min) 9 ± 1 8 ± 1 10 ± 2 NS
AdBglII, Control adenovirus; AdD Rb, adenovirus containing the gene that encodes the mutant retinoblastoma protein; NS, not significant.
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imately 10% and had dilated approximately 40%
(Table II). Mean blood flow had increased approxi-
mately 50%, although this may have reflected the
reduced level of anesthesia required for graft harvest
as compared with implantation. Of note, two of six
grafts that were found to be occluded exhibited mean
blood flows of less than 2.0 mL/min at the time of
implantation.
There were no differences in external measure-
ments, mean blood flow, luminal diameter, or medi-
al thickness among the three groups (Table II).
However, the grafts that were exposed to AdD Rb
exhibited a 22% reduction in neointimal thickness, a
difference that reached statistical significance at the
.05 level (Table II, Fig 4). There were no differences
in serum chemistries, liver enzymes, coagulation
profiles, or hematologic parameters among the three
groups (data not shown).
DISCUSSION
Systemic veins that are transplanted into the arte-
rial circulation react by thickening. This occurs
because the profound increases in wall tension and
shear stress are transduced by VSMCs, which
respond with hypertrophy and proliferation. In ani-
mals, this process is self limited and intimal thicken-
ing generally ceases once wall tension and shear
stress have normalized.1 In humans, however, the
process can continue unchecked and the resultant
lesion of intimal hyperplasia can grow to occlude the
lumen, which causes hemodynamic compromise and
thrombosis.
Attempts at attenuating vein graft intimal thick-
ening in experimental animals generally have been
successful. Good results have been achieved through
systemic administration of a variety of antiprolifera-
tive agents exploiting multiple mechanisms of action.
Table II. Graft characteristics at the time of death
Vehicle (n = 13) AdBglII (n = 11) AdD Rb (n = 12) P value
Patent grafts 10 (77%) 10 (91%) 10 (83%) NS
Graft length (mm) 27 ± 1 26 ± 1 26 ± 1 NS
External diameter (mm) 5.8 ± 0.4 5.7 ± 0.4 6.1 ± 0.3 NS
Mean blood flow (mL/min) 14 ± 2 15 ± 2 14 ± 2 NS
Lumen diameter (mm) 4.5 ± 0.2 4.4 ± 0.2 4.7 ± 0.1 NS
Medial thickness (m m) 72 ± 10 85 ± 7 69 ± 9 NS
Neointimal thickness (m m) 77 ± 7 75 ± 5 60 ± 5 .05
AdBglII, Control adenovirus; AdD Rb, adenovirus containing the gene that encodes the mutant retinoblastoma protein; NS, not significant.
Fig 2. Identification of transferred AdD Rb adenoviral genomic DNA in rabbit external jugu-
lar vein grafts. Note presence of b -globin DNA in all specimens (right panel). HAD Rb DNA
fragments (approximately 700 base pairs) were identified only in grafts exposed to AdD Rb (left
panel). JV, Jugular vein; VG, vein graft.
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Pharmacologic prevention of restenosis in humans
has met with limited success, however.9-12 This may
reflect the limitation of animal systems in accurately
modeling the complex process of human restenosis
or the duplicity of cellular feedback mechanisms,
which tend to counteract single agent therapy.
For these reasons, some investigators have postu-
lated that sustained attenuation of VSMC prolifera-
tion may be more readily accomplished through inhi-
bition of more central intracellular signaling process-
es.13-15 With the introduction of advanced techniques
in molecular biology, including cloning and gene
insertion, it has become feasible to transiently alter the
genome of vein graft VSMCs to confer a biologic
advantage. Marker genes have been successfully trans-
ferred into experimental vein grafts in a number of
laboratories,16-21 including our own.19 “Therapeutic”
gene transfer in vein grafts was first reported by Mann
et al22 who redirected rabbit vein graft biology away
from intimal hyperplasia toward medial hypertrophy
after transfection with an HVJ-liposome complex
containing antisense oligonucleotides targeted against
cdc2 kinase and proliferating cell nuclear antigen.
Fulton et al23 demonstrated that transfection of rab-
bit external jugular vein grafts with a plasmid contain-
ing the b -adrenergic receptor–kinase-1 gene (an
Fig 3. Rabbit external jugular veins grafts exposed to vehicle (top), AdBglII (middle), or
AdD Rb (bottom) and excised after 5 days. Immunohistochemical stain with mAb specific for
HA tag. Note positive stain (brown pigment) in many endothelial cells (arrows) and VSMCs in
grafts exposed to AdD Rb. Hematoxylin stain, · 100.
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inhibitor of G-protein-coupled mitogenesis) resulted
in increased b -adrenergic receptor–kinase-1 gene
expression after 3 days and decreased intimal hyper-
plasia after 4 weeks. More recent approaches have
continued to emphasize inhibition of proliferation
through a variety of pathways. Quax et al24 success-
fully reduced neointima formation in human saphe-
nous veins in organ culture by infection with an ade-
noviral vector encoding an inhibitor of plasmin and
urokinase binding. Matsumoto et al,25 with a well-
characterized model of canine vein grafting into com-
promised outflow beds, achieved a 60% decrease in
intimal thickness after treatment with a plasmid
encoding ecNOS encapsulated within HVJ-lipo-
somes. Finally, Morishita et al26 successfully blocked
VSMC cell-cycle activation by transfection with a
decoy for the E2F transcription factor, and this strat-
egy has been adapted for use in the first clinical gene
therapy trial for the prevention of vein graft neointi-
mal hyperplasia.27
The results reported herein suggest another
strategy for limiting VSMC overgrowth in vein
grafts through manipulation of the central mediators
of cellular proliferation. Rb is a 110 to 114 kD phos-
phoprotein found primarily in the nucleus of mam-
malian species.28 It appears to function as a tumor
suppressor gene because inactivation of both copies
results in eye and other tumors. It is phosphorylated
Fig 4. Rabbit external jugular veins grafts exposed to vehicle (top), AdBglII (middle), or
AdD Rb (bottom) and perfusion-fixed after 4 weeks. Arrows denote border between neointima
and media. Hematoxylin and eosin stain, · 40.
at several points during the cell cycle29,30 and is
therefore believed to be a regulator of cell division.13
Specifically, the underphosphorylated form of Rb
inactivates transcription factors E2F and Elf-1 and
arrests the cell in G1.31 Association with a cyclin-
dependent kinase (probably cdc2) leads to phospho-
rylation, which disrupts the Rb/E2F complex and
allows the expression of genes essential for entering
the S phase. Thus, a cell saturated with the under-
phosphorylated form of Rb cannot cycle. The addi-
tion of the constitutively active Rb protein has been
shown to inhibit E2F-dependent and Elf-1-depen-
dent transcription and cell cycle progression in P19
cells,32 T cells,29,31,33,34 and VSMCs,35 and in mod-
els of arterial restenosis.35,36
In this study, exposure of rabbit external jugular
veins to a single dose of high-titer Ad D Rb for 10
minutes at 120 mm Hg induced significant trans-
gene expression after 5 days, which subsequently led
to a 22% reduction in neointimal thickening at 4
weeks. The advantages to this approach are believed
to include the following: (1) the requirement of a
single dose of vector that is administered ex vivo, (2)
transgene expression that is most active during the
initial phases of cell cycling2 but then is dissipated in
the ensuing weeks,35 (3) the use of a cytostatic (as
opposed to cytotoxic) strategy that theoretically pre-
serves endothelial cell and VSMC viability, and (4)
permission of some degree of VSMC proliferation
and thickening to allow for vein adaptation and pre-
vent aneurysm formation.
Despite these attractive features, several limita-
tions of this study and strategy must be recognized.
First, adenoviral exposure has been associated with
significant inflammation (and increased cellular pro-
liferation)37 that could negatively affect graft func-
tion and patency. In this study, the degree of inflam-
mation was assessed by means of light microscopy
only, so significant changes in humoral immunity or
adhesion molecule expression would not have been
detected. Second, transgene expression was con-
firmed at only one early time point (5 days), and it
is unlikely that expression persisted much past 5
weeks on the basis of previous studies.35 The tran-
sient nature of adenoviral-mediated gene transfer is
a major drawback to its use in vascular tissue, and
alternative strategies, including the use of adeno-
associated virus particles, are actively being investi-
gated.38-42 Lastly, the degree of inhibition of neoin-
timal thickening (22%) was less than half that
observed in models of arterial restenosis.35,36 This
may reflect the fact that the hemodynamic stimulus
for vein graft thickening is continuous, while injury
produced by inflation of a balloon-catheter in arter-
ies is a single discrete event. Thus, studies of longer
duration with this model will be necessary to ensure
that neointimal thickening is truly inhibited and not
simply delayed.
In conclusion, exposure of rabbit external jugu-
lar vein grafts to a single dose of high-titer AdD Rb
for 10 minutes at 120 mm Hg resulted in efficient
transgene transfer and expression and a 22% reduc-
tion in neointimal thickening. With this delivery sys-
tem, adenoviral-mediated D Rb gene transfer is high-
ly efficient and leads to a significant reduction in
vein graft neointimal thickening without appreciable
vein graft dilatation or aneurysm formation.
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Dr Jon Matsumura (Chicago, Ill). In some applica-
tions of gene therapy, there are concerns about the
immunologic reactions with adenoviral vectors. You have
used a fully immunocompetent in vivo model with these
rabbits. Have you investigated what possible immunolog-
ic effects your influenza tag or adenoviral vector have on
the neointimal hyperplasia? Have you noticed any inflam-
matory cell infiltrates in either AdBglp or AdD Rb animals?
It seems that there is a small amount of medial thick-
ening in the AdBglp group. When I looked at your histol-
ogy there, it looked like there might be a cellular infiltrate.
Perhaps, you can comment on that.
Dr Lewis B. Schwartz. We did not specifically investi-
gate the inflammatory response, although others have
found upregulation of adhesion molecules and cellular
infiltration. With light microscopy, we did not appreciate
any significant inflammatory cell infiltration with this
gene, and this is in agreement with two other studies that
used the retinoblastoma adenoviral vector in arteries.
The problem with the immune response, in my view, is
not so much the stimulation of immune cellular infiltrates,
but that transgene expression will be attenuated as immune
cells recognize it as a foreign antigen. For that reason, we
have begun investigations with adeno-associated viral vec-
tors, although we have no preliminary results as of yet.
Dr John Hoch (Madison, Wis). In the past few years,
we and other investigators have been investigating the rel-
ative contribution of the adventitia to remodelling when
we place veins in the arterial circulation and even follow-
ing balloon injury in arteries. I wonder have you gone on
to perform these experiments, placing your adenoviral vec-
tors on the adventicial surface or in combination with inti-
mal and adventicial transfection?
Dr Schwartz. That is a good question. We have not
done that in this study, but we have had some experience
with using vectors that express the lacZ gene. First of all,
adventitial exposure alone does not result in efficient gene
incorporation or expression. Intraluminal exposure with-
out pressurization was similarily inefficient. The best strat-
egy was clearly a combination of intraluminal exposure
with pressurization.
We also have performed some gene transfer experi-
ments with human veins in culture. Intraluminal pressur-
ization with adenoviral vectors does result in significant
endothelial gene transfer but only minimal activity in the
smooth muscle cells. An interesting finding that we have
observed is that intraluminal exposure also results in a
moderate amount of adventitial staining, which suggests
the existence of microscopic vaso vasorum-type channels.
So, I think the adventitia does play a role, although this
particular gene transfer model works best with intralumi-
nal pressurized exposure.
Dr Peter Gloviczki (Rochester, Minn). My question is
whether you have compared single grafts implanted into
different animals or whether you had the opportunity to
compare one graft with another implanted to the opposite
side of the same animal?
Dr Schwartz. We implanted one graft per animal.
Dr Gloviczki. Well, then you may have the problem
that some animals develop more intimal hyperplasia than
others. If you could compare a treated graft implanted to
one side of the animal with an untreated graft implanted
to the opposite side of the same animal, then we should be
more sure that the change that we see is indeed a result of
gene transfer.
Dr Schwartz. I know exactly what you mean. This ani-
mal model is quite variable, and the small standard error bars
require many animals to achieve. It is customary to operate
on a large number of animals in these types of experiments
because the vein grafts simply do not develop that much inti-
mal thickening—certainly nothing that you would be excis-
ing in the operating room. For this reason, we are actively
trying to develop a better animal model in which the intimal
hyperplastic response is more pronounced.
Dr Patrick O’Hara (Cleveland, Ohio). This may be a
naive question, but how do you keep the virus from
spreading? I know that at 5 days you did not notice virus
in the contralateral carotid, if I understood things correct-
ly. I guess it is a nonreplicating gene. But how do you know
what is going to happen over time? Can these genes mutate
and then continue to spread? How is that controlled?
Dr Schwartz. The virus spreads very little because it is
entirely removed before grafting, and systemic exposure is
minimized. This is the main reason that gene therapy is such
an attractive approach to the problem of vein graft stenosis.
We have looked for copies of the transgene in other
anatomic locations, including contralateral vein and ster-
nomastoid muscle. As you know, polymerase chain reac-
tion is fairly sensitive, and there simply are no copies of the
gene in any of these tissues.
Dr Howard Greisler (Maywood, Ill). I have one quick
comment and one quick question.
I want to get back to Dr Matsumura’s question. I think
it is true that the immune response to adenoviral vector is
probably important in humans. But in terms of the hemag-
glutinin tag itself, that is probably not relevant in these
results. One can create a mitogen with or without being
fused in frame to the hemagglutinin tag as a chimera, and
there is absolutely no difference in mitogenic activity.
But in terms of these results, it is being presented as
important because there is a significant decrease in the
degree of hyperplasia. But, me being a pessimist, I might
say that 22% is not a whole heck of a lot, and there are still
60 microns, or 78%, of intimal hyperplasia at this one time
point, which I guess was 28 days.
Are you already starting to look at later time points?
Because there are a lot of data with a lot of things in ani-
mal models that show a transient inhibition of intimal
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hyperplasia, which later on catches up and all things
become equally hyperplastic.
Dr Schwartz. Well, that is a good point. At 22%, we
were a little bit disappointed. We thought the response
would be greater on the basis of arterial studies that
showed that this vector can inhibit arterial intimal hyper-
plasia by approximately 40%.
We do not want to inhibit the process of graft thicken-
ing too much, though. I think vein grafts do not become
more frequently aneurysmal because there is this neointimal
thickening, or medial thickening, and that renders the vein
graft strong enough to withstand aneurysm formation. My
guess is that inhibiting the response 100% would not be a
good thing to do clinically. Twenty percent is what we
found in this study, without aneurysm formation or dilata-
tion, and I think that is a good place to start.
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